NCT05598320已完成2 期
A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial Evaluating Efficacy and Safety of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Children With Achondroplasia Followed by an Open Label Extension Period
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 84
- 试验地点
- 10
- 主要终点
- Annualized Growth Velocity
研究概览
简要总结
The purpose of this clinical trial was to evaluate efficacy and safety of once weekly subcutaneous (SC) doses of 100 µg TransCon CNP/kg compared to placebo on Annualized Growth Velocity after a 52-week randomized treatment period in children aged 2 to 11 years with genetically confirmed Achondroplasia. The double-blind, placebo-controlled treatment period was followed by an Open Label Extension (OLE) period of a 52-week duration.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 2 Years 至 11 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written, signed informed consent of the parent(s) or legal guardian(s) of the participant, and as required by the institutional review board/human research ethics committee/independent ethics committee (IRB/HREC/IEC).
- •Male or female, between 2 and 11 years of age (inclusive) at the time of Screening.
- •Clinical diagnosis of Achondroplasia (ACH) with documented genetic confirmation available.
- •Able to stand without assistance.
- •Parent(s)/legal guardian(s) willing and able to administer weekly SC injections of Investigational Medicinal Product (IMP) and to follow the protocol.
- •At least six months of growth and disease history from ACHieve (TCC-NHS-01) trial or comparable growth and disease history available from medical records (pending confirmation by Medical Monitor).
- •Considered eligible based on the medical history, physical examination, and the results of vital signs, ECG and clinical laboratory tests performed during the Screening period
排除标准
- •Participation (i.e., signed informed consent) in any interventional clinical trial before within 3 months prior to screening.
- •Closed epiphysis.
- •Known or suspected hypersensitivity to the IMP or related products (trehalose, tris[hydroxymethyl]aminomethane, succinate, and mPEG).
- •Had a growth disorder or medical condition other than ACH that results in short stature or abnormal growth such as severe ACH with developmental delay and acanthosis nigricans (SADDAN), hypochondroplasia, growth hormone deficiency, Turner syndrome, pseudoachondroplasia, inflammatory bowel disease, celiac disease, hypothyroidism, hyperthyroidism, pre-diabetes, or diabetes mellitus.
- •Have received any dose of prescription medications and IMP or surgical intervention intended to affect stature, growth, or body proportionality at any time.
- •Required, or anticipated to require, chronic (> 4 weeks) or repeated treatment (more than twice/year and >3 weeks/year) with systemic corticosteroids during participation in the trial. Chronic use of high-dose inhaled corticosteroids was not allowed.
- •Known history of presence of injury or disease of the growth plate(s), other than ACH, that affects growth potential of long bones.
- •Known history of any bone-related surgery affecting growth potential of long bones, such as:
- •Orthopedic reconstructive surgery for bone lengthening (e.g., procedures for leg bowing such as 8-plate are not exclusionary).
- •Cervicomedullary decompression surgery without anticipated need for repeat decompression during the time of the trial are allowed with minimum of 6 months of bone healing.
- •Ventriculoperitoneal (VP) shunt and laminectomy with full recovery are allowed with minimum of 6 months of bone healing.
- •Bone fracture within 6 months prior to screening (within 2 months for fracture of digits and buckle fractures).
- •Clinically significant findings at Screening, such as:
- •Expected to require surgical intervention during participation in the trial. Common surgeries, such as insertion of grommets, adenoidectomy, tonsillectomy, or myringotomy tube placement, are permitted.
- •Severe untreated sleep apnea or newly initiated sleep apnea treatment (e.g., Continuous Positive Airway Pressure [CPAP] in the previous 2 months prior to Screening).
- •Musculoskeletal disease, such as Salter-Harris fractures or clinical and/or radiographic evidence of severe hip pathology, or
- •Otherwise, are considered by the Investigator and Medical Monitor to make a participant unfit to receive trial treatment or undergo trial related procedures.
- •Had evidence at Screening that were consistent with severe cervicomedullary junction compression based on clinical and/or radiologic findings that indicated immediate surgical intervention was required.
- •Had a clinically significant finding or arrhythmia as determined by the investigator in consultation with the medical monitor that indicates abnormal cardiac function or conduction that includes, but was not exclusive to:
- •Repaired or unrepaired coarctation.
- •Moderate or greater complexity congenital heart disease including tetralogy of Fallot, Atrioventricular septal defects, truncus arteriosus, total anomalous pulmonary venous return, double outlet right ventricle, or single ventricle heart disease.
- •QTcF ≥ 450 msec at the Screening Visit.
- •Known history or presence of condition that impacts hemodynamic stability (such as autonomic dysfunction and orthostatic intolerance).
- •Known history or presence of the following:
- •Chronic anemia (iron deficiency anemia that is resolved or adequately treated in the Investigator's opinion was allowed).
- •Chronic renal insufficiency (GFR <60 mL/min/1.73 m2 for >3 months).
- •Chronic or recurrent illness that can affect hydration or volume status, including conditions associated with decreased nutritional intake or increased volume loss.
- •Known history or presence of malignant disease.
- •Participant with serum 25-hydroxy-vitamin D (25OHD) levels of <30 nmol/L (<12 ng/mL) at Screening Visit were excluded. Participants with 25OHD levels between 30-50 nmol/L (12-20 ng/mL) were randomized provided treatment with Vitamin D supplementation was initiated.
- •Any disease or condition that, in the opinion of the Investigator, may make the participant unlikely to fully complete the trial, may confound interpretation of trial results, or may present undue risk from receiving trial treatment. This included family situations, complications or manifestations, or medications that might impact safety or be considered confounding.
- •Sexually active male and female participants and female partners of male participants of childbearing potential not using a highly effective form of contraceptive for the entire trial period and for 90 days after last dose of trial treatment.
研究组 & 干预措施
Navepegritide
Experimental
Participants received Navepegritide (TransCon CNP) 100 micrograms per kilogram (µg/kg) delivered once weekly by subcutaneous injection for a treatment period of up to 52 weeks.
干预措施: Navepegritide (TransCon CNP) (Drug)
Placebo for Navepegritide
Placebo Comparator
Participants received placebo matched for Navepegritide (TransCon CNP) 100 µg/kg delivered once weekly by subcutaneous injection for a treatment period of up to 52 weeks.
干预措施: Placebo for Navepegritide (TransCon CNP) (Drug)
Open-Label Extension Period: Navepegritide
Experimental
Participants who completed the 52-week treatment period continued into the open-label extension period and received treatment with navepegritide (TransCon CNP) doses up to Week 104. All participants received navepegritide at a dose of 100 μg/kg/week.
干预措施: Navepegritide (TransCon CNP) (Drug)
结局指标
主要结局
Annualized Growth Velocity
时间窗: 52 weeks
cm per year
Annualized Growth Velocity (AGV) at Week 52
时间窗: At Week 52
Annualized growth velocity is defined as (height - baseline height)/(date of height assessment - date of baseline) \* 365.25. Annualized growth velocity reported in terms of centimeters (cm) per year. Missing values at Week 52 were imputed by a multiple imputation method.
次要结局
- Height Z-score(52 weeks)
- Change From Baseline in Height Z-score (ACH-specific) at Week 52(Baseline, Week 52)
- Change From Baseline in Height Z-score (CDC-Based) at Week 52(Baseline, Week 52)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
2 期
The Effects of Aplindore on the Treatment of Signs and Symptoms of Parkinson's DiseaseEarly Stage Parkinson's DiseaseNCT00623324Ligand Pharmaceuticals40
招募中
2 期
A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.Carcinoma, HepatocellularNCT06349980Shanghai Henlius Biotech117
已完成
2 期
Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic ChemotherapyNausea and Vomiting, Chemotherapy-InducedChemotherapy-Induced Nausea and VomitingNCT00104403GlaxoSmithKline722
已完成
2 期
Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary TuberculosisPulmonary TuberculosisNCT00401271Otsuka Frankfurt Research Institute GmbH54
已完成
2 期
NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective DisorderTardive DyskinesiaNCT01393600Neurocrine Biosciences37